^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGFR-1 antagonist

    Related drugs:
    4d
    Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC (clinicaltrials.gov)
    P1, N=36, Recruiting, University of Chicago | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • zanzalintinib (XL092)
    17d
    Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery (clinicaltrials.gov)
    P2, N=45, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2029 --> Oct 2030
    Trial completion date
    |
    zanzalintinib (XL092)
    30d
    Maintenance Zanzalintinib With Etoposide After HDCT in GCT (clinicaltrials.gov)
    P1/2, N=38, Recruiting, Indiana University | Not yet recruiting --> Recruiting | Trial completion date: Mar 2032 --> Sep 2031
    Enrollment open • Trial completion date
    |
    etoposide oral • zanzalintinib (XL092)
    1m
    Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Halaven (eribulin mesylate) • zanzalintinib (XL092)
    1m
    Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. (PubMed, Lancet)
    STELLAR-303 is the first phase 3 trial to show a significant improvement in overall survival with an immunotherapy-based regimen, zanzalintinib-atezolizumab, in patients with relapsed or refractory metastatic colorectal cancer that is not MSI-H or dMMR. This combination represents a chemotherapy-free treatment option with a novel mechanism of action for heavily pretreated patients in need of improved therapies.
    P3 data • Journal
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • Stivarga (regorafenib) • zanzalintinib (XL092)
    1m
    STELLAR-303: Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=901, Active, not recruiting, Exelixis | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Aug 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR • RAS mutation
    |
    Tecentriq (atezolizumab) • Stivarga (regorafenib) • zanzalintinib (XL092)
    2ms
    Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, University of Chicago | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • zanzalintinib (XL092)
    2ms
    Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer (clinicaltrials.gov)
    P1, N=36, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • zanzalintinib (XL092)
    2ms
    A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    zanzalintinib (XL092)
    3ms
    Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery (clinicaltrials.gov)
    P2, N=45, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    zanzalintinib (XL092)
    3ms
    Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Washington University School of Medicine | Initiation date: Jul 2025 --> Oct 2025 | Trial primary completion date: Aug 2029 --> Nov 2029
    Trial initiation date • Trial primary completion date
    |
    paclitaxel • zanzalintinib (XL092)
    5ms
    Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, University of Chicago | Initiation date: Jun 2025 --> Oct 2025
    Trial initiation date
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • zanzalintinib (XL092)